Generic Name: fluocinolone acetonide intravitreal implant
Brand Name: Iluvien
Manufacturer: Knight Therapeutics Inc.
Indications: diabetic macular edema
Manufacturer Requested Reimbursement Criteria1: Indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
Submission Type: New
Project Status: Active
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input posted||March 06, 2019|
|Patient group input closed||April 25, 2019|
|Patient input summary sent for review to patient input groups||-|
|Patient group comments on input summary closed||-|
|Submission received||April 03, 2019|
|Submission accepted for review||April 17, 2019|
|Review initiated||April 18, 2019|
|Draft CADTH review report(s) sent to applicant||July 04, 2019|
|Comments from applicant on draft CADTH review report(s) received||July 15, 2019|
|Redaction requests from applicant on draft CADTH review report(s) received||July 22, 2019|
|CADTH review team's comments on draft CADTH review report(s) sent to applicant||August 09, 2019|
|Canadian Drug Expert Committee (CDEC) meeting||August 21, 2019|
|CDEC recommendation & redacted CADTH review report(s) sent to applicant and drug plans||September 03, 2019|
September 05, 2019